Cyclophosphamide, Azathioprine,prednisone,methylprednisolone — Competitive Intelligence Brief

Cyclophosphamide, Azathioprine,prednisone,methylprednisolone (Cyclophosphamide, Azathioprine,prednisone,methylprednisolone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressive combination therapy. Area: Immunology.

marketed Immunosuppressive combination therapy Immunology Small molecule

Target snapshot

Cyclophosphamide, Azathioprine,prednisone,methylprednisolone (Cyclophosphamide, Azathioprine,prednisone,methylprednisolone) — Assistance Publique - Hôpitaux de Paris. This combination regimen suppresses the immune system through multiple pathways: cyclophosphamide and azathioprine inhibit lymphocyte proliferation, while corticosteroids (prednisone and methylprednisolone) broadly suppress inflammatory and immune responses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cyclophosphamide, Azathioprine,prednisone,methylprednisolone TARGET	Cyclophosphamide, Azathioprine,prednisone,methylprednisolone	Assistance Publique - Hôpitaux de Paris	marketed	Immunosuppressive combination therapy
ATG/PTCy	ATG/PTCy	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	marketed	Immunosuppressive combination therapy
Mycophenolate+Tacrolimus+Prednisone	Mycophenolate+Tacrolimus+Prednisone	Fundação Pró Rim	marketed	Immunosuppressive combination therapy	T-cell proliferation and activation (multiple targets: IMPDH, calcineurin, glucocorticoid receptor)
tacrolimus OD, mycophenolic acid, prednisolone	tacrolimus OD, mycophenolic acid, prednisolone	University Medical Center Groningen	marketed	Immunosuppressive combination therapy	Calcineurin (tacrolimus); IMPDH (mycophenolic acid); glucocorticoid receptor (prednisolone)
Zenapax®, CellCept® and prednisolone	Zenapax®, CellCept® and prednisolone	University of Oslo School of Pharmacy	marketed	Immunosuppressive combination therapy	IL-2 receptor (daclizumab); inosine monophosphate dehydrogenase (mycophenolate mofetil); glucocorticoid receptor (prednisolone)
ATG+mycophénolate mofétil+tacrolimus	ATG+mycophénolate mofétil+tacrolimus	University Hospital, Toulouse	marketed	Immunosuppressive combination therapy	T lymphocytes (ATG); IMPDH (mycophenolate mofetil); calcineurin (tacrolimus)
Sirolimus+MMF or MPS or AZA+Steroid	Sirolimus+MMF or MPS or AZA+Steroid	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Immunosuppressive combination therapy	mTOR (sirolimus); IMPDH (MMF/MPS); purine synthesis (AZA); glucocorticoid receptor (steroid)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressive combination therapy class)

1. University Hospital, Brest · 2 drugs in this class
2. Pfizer · 2 drugs in this class
3. Fundação Pró Rim · 2 drugs in this class
4. Haukeland University Hospital · 1 drug in this class
5. Imperial College Healthcare NHS Trust · 1 drug in this class
6. Jinnah Postgraduate Medical Centre · 1 drug in this class
7. Novartis · 1 drug in this class
8. Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class
9. Swiss Cancer Institute · 1 drug in this class
10. University Hospital Freiburg · 1 drug in this class